Posted by Michael Wonder on 11 Aug 2025
Lantheus announces FDA acceptance of NDA for new formulation for market leading PSMA PET imaging agent
6 August 2025 - PDUFA date set for March 6, 2026
Lantheus today announced that the FDA has accepted a new drug application for a new formulation of its F 18 PSMA imaging agent filed by its affiliate, Aphelion.
